Browsing Tag
Inc.
194 posts
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
Asana, Inc. (NYSE: ASAN) targets $858m FY27 revenue as AI expansion and CFO shift signal strategic reset
Asana (NYSE: ASAN) targets up to $858M in FY27 revenue while expanding its AI platform and appointing a new CFO. What does this mean for investors?
When cloud meets conflict: What the Gulf drone strikes mean for Amazon Web Services
Drone strikes damage Amazon Web Services data centers in UAE and Bahrain. Explore what this means for Amazon.com, Inc. and global cloud risk.
Will autonomous maritime counter-drone systems redefine Red Cat Holdings, Inc.’s growth trajectory?
Red Cat Holdings, Inc. integrates Allen Control Systems’ Bullfrog into Blue Ops platforms. Discover what this means for autonomous counter-drone defense.
What NUBURU, Inc.’s Maddox Defense venture means for NATO-aligned distributed manufacturing
NUBURU, Inc. partners with Maddox Defense on mobile drone manufacturing. Explore what this means for defense strategy and investor sentiment today.
Can drone data become the next high-margin growth driver for Cellebrite Ltd.? (NASDAQ: CLBT)
Cellebrite Ltd. expands into drone forensics with SCG Canada, Inc. acquisition. Discover how UAV data could reshape AI-powered investigations.
Does FDA clearance across three HLA subtypes de-risk TScan Therapeutics’ platform strategy?
FDA clears TSC-102-A01 and TSC-102-A03 for TScan Therapeutics. Explore how expanded HLA reach reshapes its heme cell therapy strategy.
Will mavorixafor’s EU path mirror its U.S. regulatory breakthrough in WHIM syndrome?
X4 Pharmaceuticals (NASDAQ: XFOR) wins EMA backing for mavorixafor. Explore what EU approval could mean for revenue, risk, and rare disease strategy.
How FDA-aligned endpoints position inFoods IBS alongside drug therapies
Biomerica, Inc. aligns inFoods IBS with FDA drug endpoints and secures Medicare pricing. See what this means for IBS competitors and investors.
SCY-247 intravenous trial signals strategic shift in SCYNEXIS, Inc.’s antifungal pipeline
SCYNEXIS, Inc. advances IV SCY-247 into Phase 1. Discover what this signals for antifungal resistance and hospital markets.